TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases

Stopped Study withdrawn due to change in treatment landscape for HER2+ metastatic breast cancer.

Conditions

• Breast Cancer
• Brain Metastases
• HER2-positive Breast Cancer
• CNS Disease

Interventions

• DRUG: Tucatinib
• DRUG: Pembrolizumab
• DRUG: Trastuzumab

Sponsor

Reva Basho

Collaborators

• [object Object]
• [object Object]